Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Eye Drops in Neovascular AMD
NCT01362348Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pazopanib in neovascular age-related macular degeneration (NVAMD), sponsored by GSK. Started Jul 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01362348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362348.